Sees FY22 adjusted EBITDA of $50M-$53M,. The lower guidance ranges relative to prior expectations were primarily driven by lower than expected visit volume and higher than expected costs associated with the company’s employee health benefits program.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LFST: